Cited 5 times in
Open-label, uncontrolled, clinical trial of barnidipine hydrochloride in Korean patients with renal parenchymal hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박형천 | - |
dc.contributor.author | 한대석 | - |
dc.date.accessioned | 2019-11-11T05:23:10Z | - |
dc.date.available | 2019-11-11T05:23:10Z | - |
dc.date.issued | 2000 | - |
dc.identifier.issn | 0011-393X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171832 | - |
dc.description.abstract | Background: Barnidipine hydrochloride is a calcium channel blocker that is administered in a single daily dose. It has been shown to be effective in lowering blood pressure in Japanese patients with essential hypertension, renal parenchymal hypertension, and renovascular hypertension. Objective: The purpose of this study was to assess the antihypertensive efficacy and tolerability of barnidipine hydrochloride in Korean patients with renal parenchymal hypertension. Methods: This open-label, uncontrolled study used a dose-escalation design, with 5 to 15 mg barnidipine administered once daily for 4 to 8 weeks. Korean patients with renal parenchymal hypertension were enrolled. Results: Of the 31 patients enrolled, 30 (15 men and 15 women; mean age, 45.1 ± 10.4 years; mean body weight, 62.5 ± 10.4 kg; mean sitting systolic blood pressure [SBP], 158.0 ± 13.2 mm Hg; mean diastolic blood pressure [DBP], 101.8 ± 7.1 mm Hg) completed the entire schedule of drug administration. One patient discontinued hospital visits at 2 weeks. In 3 patients treated with barnidipine 5 mg/d for 4 weeks, mean SBP and DBP were 131.7 ± 16.1 mm Hg and 85.0 ± 5.0 mm Hg, respectively, after 4 weeks of treatment compared with 160.0 ± 34.6 mm Hg and 105.0 ± 13.2 mm Hg at baseline. In 15 patients treated with barnidipine 5 mg/d for 2 weeks and 10 mg/d for 4 weeks, mean SBP and DBP were 138.3 ± 7.9 mm Hg and 84.3 ± 8.0 mm Hg, respectively, 6 weeks after treatment compared with 160.7 ± 13.7 mm Hg and 102.7 ± 9.0 mm Hg at baseline (P < 0.05). In 12 patients treated with barnidipine 5 mg/d for 2 weeks, 10 mg/d for 2 weeks, and 15 mg/d for 4 weeks, mean SBP and DBP were 139.6 ± 8.7 mm Hg and 85.8 ± 8.7 mm Hg, respectively, 8 weeks after treatment compared with 158.3 ± 13.7 mm Hg and 100.8 ± 6.0 mm Hg at baseline (P < 0.05). Mean sitting SBP after 4 to 8 weeks of treatment with barnidipine was 139.9 ± 8.5 mm Hg (mean reduction, 18.1 mm Hg [11.4%]) and mean sitting DBP was 85.5 ± 7.5 mm Hg (mean reduction, 16.3 mm Hg [16%]). Sitting heart rate did not change after treatment with barnidipine. Barnidipine was well tolerated; mild adverse events occurred in 5 of 30 patients (17%) and included facial flushing (13%), tachycardia (13%), and headache (7%). Conclusions: The results suggest that barnidipine is effective in reducing systemic hypertension and is well tolerated in this sample of Korean patients with renal parenchymal hypertension. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Excerpta Medica | - |
dc.relation.isPartOf | Current Therapeutic Research, Clinical and Experimental | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Open-label, uncontrolled, clinical trial of barnidipine hydrochloride in Korean patients with renal parenchymal hypertension | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyeong Cheon Park | - |
dc.contributor.googleauthor | Kun Ho Kwon | - |
dc.contributor.googleauthor | Hyun Jin Noh | - |
dc.contributor.googleauthor | In Hee Lee | - |
dc.contributor.googleauthor | Shin Wook Kang | - |
dc.contributor.googleauthor | Kyu Hun Choi | - |
dc.contributor.googleauthor | Sung Kyu Ha | - |
dc.contributor.googleauthor | Ho Yung Lee | - |
dc.contributor.googleauthor | Dae Suk Hana | - |
dc.contributor.googleauthor | Minoru Yamamoto | - |
dc.identifier.doi | 10.1016/S0011-393X(00)90020-1 | - |
dc.contributor.localId | A01759 | - |
dc.contributor.localId | A04272 | - |
dc.relation.journalcode | J03690 | - |
dc.identifier.eissn | 1879-0313 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0011393X00900201 | - |
dc.subject.keyword | barnidipine hydrochloride | - |
dc.subject.keyword | calcium channel blocker | - |
dc.subject.keyword | renal parenchymal hypertension | - |
dc.subject.keyword | blood pressure | - |
dc.contributor.alternativeName | Park, Hyeong Cheon | - |
dc.contributor.affiliatedAuthor | 박형천 | - |
dc.contributor.affiliatedAuthor | 한대석 | - |
dc.citation.volume | 61 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 927 | - |
dc.citation.endPage | 937 | - |
dc.identifier.bibliographicCitation | Current Therapeutic Research, Clinical and Experimental, Vol.61(12) : 927-937, 2000 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.